
Articles
-
3 weeks ago |
healio.com | Shawn M. Carter |Gina Brockenbrough
Key takeaways: Risk for cardiovascular death increased with disease stage, but risk was similar for stages 0 and 1. Survival time was reduced by about 8.1 months for stage 4 vs. stage 0. Higher stages of cardiovascular-kidney-metabolic syndrome may correlate to increased risk of cardiovascular mortality, according to a longitudinal study of U.S. adults.
-
3 weeks ago |
healio.com | Jill Rollet |Gina Brockenbrough
Read more Key takeaways: More than 20% of patients on hemodialysis reported cannabis use, but only 8% had ever been asked about it. Cannabis does not interfere with dialysis but could interact with drugs used by this population. Patients with kidney disease may be using cannabis recreationally or to treat symptoms without the knowledge of their health care team, according to results of a small survey of patients from a hemodialysis clinic in Canada.
-
1 month ago |
healio.com | Jill Rollet |Gina Brockenbrough
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
-
1 month ago |
healio.com | Jill Rollet |Gina Brockenbrough
An aging population with more chronic metabolic disorders, an aging nursing workforce and a dearth of nephrology fellows may signal a continued decrease in the nephrology workforce, according to Healio | Nephrology News & Issues sources. “A shortage of nephrologists since the start of the specialty has always put extra workloads on those in practice. Remember the projections of potential patients and costs in 1972 when Congress approved Medicare for dialysis payment?
-
1 month ago |
healio.com | Shawn M. Carter |Gina Brockenbrough |Ronald D. Perrone
Key takeaways: Patients on tolvaptan had an eGFR decline of 1.40 mL/min/1.73 m² per year. Annual rate of eGFR decline in patients on tolvaptan was slower than in historical controls. Routine use of tolvaptan in clinical practice may slow eGFR decline for patients with autosomal dominant polycystic kidney disease compared with historical controls, data show.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →